FDA Okays Evolocumab Add-On for FH in Children Aged 10 and Up

The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age and older with either heterozygous or homozygous familial hypercholesterolemia (FH). 

Approval was based on randomized trials of evolocumab in both types of FH, the agency notes in a statement released September 24.

The HAUSER-RCT trial included patients aged 10 to 17 years with heterozygous FH who were already on statins with or without ezetimibe. They were randomly assigned to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo for 24 weeks. The results, published in the New England Journal of Medicine in August of 2020, showed an average 38% reduction in LDL cholesterol among treated patients.  

In a separate study of pediatric patients with homozygous FH aged 11-17 years, those treated with evolocumab 420 mg monthly by subcutaneous injection for 80 weeks had an average 14% reduction in LDL cholesterol compared with baseline, the release said.

Patients with a serious hypersensitivity reaction to evolocumab or its excipients must not take the drug, the FDA said. “If signs or symptoms of hypersensitivity occur, patients must stop treatment,” it notes. Common side effects in pediatric patients include nasopharyngitis, headache, oropharyngeal pain, and upper respiratory tract infection. 

Evolocumab was approved in 2015 for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous and homozygous familial hypercholesterolemia or clinical evidence of atherosclerotic cardiovascular disease who require further LDL cholesterol lowering.

In 2017, the FDA approved a supplemental application for evolocumab to prevent myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. It was also approved as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia to reduce LDL cholesterol. 

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Caregivers thumbnail

Caregivers

Aging parentsBy Mayo Clinic Staff Adult children often serve as caregivers for aging parents. Although monitoring the health and independence of parents may seem daunting, there are steps you can take to ease stress and be well prepared. Start with some basic questions. Are your parents safe in their home? Are they able to take
Read More
20 Winter Salad Recipes to Make This Holiday Season thumbnail

20 Winter Salad Recipes to Make This Holiday Season

Not a lot of people realize this, but winter is actually an amazing time for salads—and winter salad recipes are among the season’s very best culinary offerings. First of all, just because it's cold out doesn't mean you won't have access to fresh and flavorful produce. In fact, some fruits and veggies—like juicy citrus and…
Read More
Spots still open for IAFP’s Pre-meeting Workshops thumbnail

Spots still open for IAFP’s Pre-meeting Workshops

Seats still remain for IAFP’s pre-meeting workshops and those looking to get a food safety head start can attend any one of the four workshops offered by IAFP in the days leading up to the annual meeting.  The workshops are designed for those in industry, academia, students and government. The International Association for Food Protection…
Read More
Sending Out an SOS: Science of Suicide thumbnail

Sending Out an SOS: Science of Suicide

Opinion > Suicidologist's Soliloquy — A brief, but important, call to action by Russell Copelan, MD August 16, 2023 Copelan is an expert in emergency department psychiatry. Suspicious to the very limits of my personality, imagination, and training, I admit that I experience instances of intense exasperation and sadness with the current field of suicidology.
Read More
Index Of News